Antibodies specific for hyperphosphorylated tau and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10196439-B2
Application number	US-201615207836-A
Country	US
Kind code	B2
Filing date	Jul 12, 2016
Priority date	Jul 13, 2015
Publication date	Feb 5, 2019
Grant date	Feb 5, 2019

Abstract

The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

First claim

The invention claimed is:

1. An immunoglobulin capable of immunospecifically binding to a hyperphosphorylated variant of human tau (SEQ ID NO: 33), wherein the phosphoserine at tau position 396 is required for binding, wherein said immunoglobulin molecule is a monoclonal antibody, or an epitope-binding fragment thereof, and wherein phosphorylation of S 404 of tau does not substantially increase binding, wherein said monoclonal antibody, or epitope-binding fragment thereof comprises:
(a) a Light Chain CDR1 consisting of the amino acid sequence of SEQ ID NO:9;
(b) a Light Chain CDR2 consisting of the amino acid sequence of SEQ ID NO:10;
(c) a Light Chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 1;
(d) a Heavy Chain CDR1 consisting of the amino acid sequence of SEQ ID NO:12;
(e) a Heavy Chain CDR2 consisting of the amino acid sequence of SEQ ID NO:13; and
(f) a Heavy Chain CDR3 consisting of the amino acid sequence of SEQ ID NO:14.

2. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is a monoclonal antibody or a bispecific antibody, having an Fc domain.

3. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is an epitope-binding fragment of said monoclonal antibody that is selected from the group consisting of: an Fv fragment, an Fv fragment fused to an Fc domain, a Fab fragment, a Fab′fragment, a F(ab) 2 fragment, a single V H variable domain and a single VL variable domain.

4. The immunoglobulin molecule according to claim 1 , wherein said antibody is humanized.

5. The immunoglobulin molecule according to claim 1 , wherein said antibody comprises:
(1) a Light Chain consisting of the amino acid sequence of SEQ ID NO: 15; or
(2) a Heavy Chain consisting of the amino acid sequence of SEQ ID NO: 16; or
(3) said Heavy Chain and said Light Chain.

6. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule capable of immunospecifically binding to said hyperphosphorylated variant of human tau (SEQ ID NO:33) is selective for an amino acid motif of said hyperphosphorylated tau that has the sequence:
—Y—K—S(phosphorylated)-P—

wherein Y is tyrosine, K is lysine, P is proline and S(phosphorylated) is serine with a phosphorylated hydroxyl side chain.

7. The immunoglobulin molecule according to claim 1 , wherein said molecule further comprises a moiety for increasing the in vivo half-life of the molecule.

8. The immunoglobulin molecule according to claim 1 , wherein said antibody is elicited against a bi-phosphorylated peptide fragment of said hyperphosphorylated variant of human tau (SEQ ID NO:33) comprising at least 18 consecutive amino acid residues of the peptide:
TDHGAEIVYK {p} SPVVSGDT {p} SPRHL (SEQ ID NO:37).

9. The immunoglobulin molecule according to claim 1 , wherein said antibody exhibits at least a 50-fold greater specificity for hyperphosphorylated tau from AD-diseased patients or AD-diseased tau, relative to tau from age-matched healthy controls.

10. The immunoglobulin molecule according to claim 1 , wherein said antibody is a monoclonal antibody expressed by a hybridoma that was isolated by screening hybridomas with human pathological and non-pathological tau to isolate clones that:
(i) are immunospecific towards the phospho-epitope S396; and
(ii) specifically recognize hyper-phosphorylated tau from human Alzheimer's disease brains;
wherein said monoclonal antibody and epitope-binding fragments thereof are able to discriminate between pathological and non-pathological human tau protein.

11. The immunoglobulin molecule according to claim 1 , wherein the antibody or epitope-binding fragment thereof is detectably labeled.

12. The immunoglobulin molecule according to claim 11 , wherein the detectable label is a fluorescent label, a chemiluminescent label, a paramagnetic label, a radioisotopic label or an enzyme label.

13. A pharmaceutical composition comprising the immunoglobulin molecule according to claim 1 , and a pharmaceutical acceptable carrier.

14. A nucleic acid encoding the immunoglobulin molecule according to claim 1 .

15. A method of slowing or attenuating the progress or severity of Alzheimer's disease or other tauopathy in a subject in need thereof, said method comprising administering to said subject an effective amount of the immunoglobulin molecule of claim 1 .

16. A kit comprising a therapeutically effective amount of the pharmaceutical composition according to claim 13 , wherein a therapeutically effective amount is an amount sufficient to stabilize, slow, attenuate or delay the progression of Alzheimer's disease or other tauopathy.

17. A method of diagnosing or imaging Alzheimer's disease or other tauopathy in a subject in need thereof, wherein said method comprises administering to said subject an amount of the detectably-labeled immunoglobulin molecule of claim 11 sufficient to detect or measure the presence or amount of said hyperphosphorylated variant of human tau in the brain of said subject; and
detecting or measuring the presence or amount of said hyperphosphorylated variant of human tau in the brain of said subject.

18. The method of diagnosing or imaging Alzheimer's disease or other tauopathy of claim 17 , wherein said detection or measurement comprises in vivo imaging of said detectably-labeled immunoglobulin molecule bound to said hyperphosphorylated variant of human tau.

19. A method of treating a tauopathy of a subject in need thereof, wherein said tauopathy is characterized by the presence of a tangle comprising hyperphosphorylated Tau, wherein said method comprises administering to said subject an amount of the immunoglobulin molecule of claim 1 sufficient to contact said hyperphosphorylated Tau, so as to result in the tangle being depleted of 90% of hyperphosphorylated tau.

20. A method of treating Alzheimer's Disease in a subject in need thereof, wherein said method comprises administering to said subject an amount of the immunoglobulin molecule of claim 1 sufficient to reduce or attenuate the accumulation of pathological tau protein in said patient.

Assignees

• H Lundbeck As

Inventors

• Pedersen Jan Torleif
• Pedersen Lars Østergaard
• Daechsel Justus Claus Alfred
• Asuni Ayodeji Abdur-Rasheed
• Rosenqvist Nina Helen
• Volbracht Christiane
• Helboe Lone
• Elvang Anders Brandt
• Sotty Florence
• Christensen Søren
• Stavenhagen Jeffrey B

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title